AstraZeneca stock: Zacks upgrades AstraZeneca to Hold as results near for AstraZeneca stock

Published on 10/20/2026 at 17:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 30, 2026, after an ESMO event on October 26. AstraZeneca stock was EUR 150.05 at Lang & Schwarz on October 20, 2026.

Analyst view and reporting date

Zacks Research upgraded AstraZeneca from Strong Sell to Hold on October 15, 2026.
AstraZeneca will report nine-month and third-quarter 2026 results on October 30, 2026.
AstraZeneca stock was at EUR 150.05 at Lang & Schwarz on October 20, 2026 at 5:06 p.m. CEST.
The latest USD 153.41 to USD 212.71 range and USD 261.2 billion market value frame the stock.

Flatlay mit Aktienzertifikat, ISIN-Karte, Stethoskop und Impfstofffläschchen — AstraZeneca plc (ISIN GB0009895292) ist als forschendes Pharmaunternehmen an internationalen Börsen wie London gelistet, Illustration mit AI erstellt.

AstraZeneca has an upgraded analyst rating and two scheduled investor dates ahead. MarketBeat reported on October 15, 2026 that Zacks Research upgraded AstraZeneca from Strong Sell to Hold. The stock was at EUR 150.05 at Lang & Schwarz on October 20, 2026 at 5:06 p.m. CEST.

Hold rating changes the tone

The Zacks decision adds a more neutral signal to the recent analyst picture. MarketBeat listed 14 Buy ratings, three Holds and one Sell among analysts in its October 11, 2026 overview, alongside an average target of USD 206.67. That count describes a broad range of views rather than a single consensus direction.

AstraZeneca's upcoming reporting calendar gives the rating a near-term test. The company is scheduled to present management at ESMO on October 26, 2026, followed by nine-month and third-quarter 2026 results on October 30, 2026, according to the AstraZeneca investor calendar.

Price position has room to move

The latest market figures put the stock's USD 153.41 to USD 212.71 52-week range in view as of October 20, 2026. The USD 261.2 billion market capitalization and 25.26 price-to-earnings ratio provide a valuation frame, while the 2.00 percent dividend yield adds an income measure. The latest reported volume was 1,070,375 shares.

What comes next for investors

The October 26 ESMO event is the next scheduled company date, followed four days later by the third-quarter results. Those dates matter because the October 15 rating change did not include a new earnings figure or a revised price target in the cited report. AstraZeneca's investor calendar also lists a November 2, 2026 London roadshow, extending the sequence of formal company meetings.

Stock stays tied to two dates

For investors, the most concrete near-term comparison is between the neutral Hold rating and the wider analyst distribution. The scheduled October 30 results will provide the next quantified test of revenue, earnings and guidance, while the October 26 event may add pipeline detail before that report.

AstraZeneca stock was at EUR 150.05 at Lang & Schwarz on October 20, 2026 at 5:06 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.